NY-MEDICREA-GROUP
The Medicrea Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, announced today that the Company will have a strong clinical and commercial presence at the Eurospine 2017 meeting in Dublin, Ireland, from the 11th to the 13th of October, where UNiD™ LAB biomedical engineers will demonstrate the Company’s UNiD™ ASI technology in their booth (#F16) and host the European Launch of their proprietary UNiD™ HUB software.
Denys Sournac, President and Chief Executive Officer, stated: “At Eurospine 2017, we will demonstrate to the international community of spine surgeons in attendance how UNiD™ ASI technology fills the void created by traditional manufacturers by launching UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to surgeon and patient. We will further expand our commercialization efforts with the U.S. launch shortly thereafter at NASS 2017, from the 25th to the 27th of October in Orlando, Florida.”
On Wednesday, October 11th, Medicrea will host an exclusive European UNiD™ HUB launch event at the Teeling Whiskey Distillery, where Dr. Evalina Burger, of University Colorado Hospital, and Thomas Mosnier, PhD, Chief Scientific Officer at Medicrea, will introduce the patented and exclusive surgical planning, analytics and data visualization capabilities of the UNiD™ HUB software and share how Medicrea enables surgeons and healthcare providers to use proprietary data science to drive improved outcomes and economic efficiencies in spine surgery.
Two podium presentations featuring the clinical results achieved with Medicrea’s patient-specific UNiD™ Rods, generated by the Company’s UNiD™ ASI systems-based technology for personalized spinal care, will be given on Friday, October 13th. The lecture details are given below:
-
Are Patient-Specific Rods Effective to Manage Adult Spinal
Deformity?
Authored by Dr. V. Fiere, Dr. H. D’Astorg, Dr. M. Szadkowski and Dr. E. Burger.
Plenary Hall - New Techniques and Imaging Session from 2:00 to 3:20pm
-
Radiographic Comparison of Patient-Specific (PS) and
Manually-Contoured Conventional (C) Rods in Adolescent Idiopathic
Scoliosis (AIS) Surgery.
Authored by Dr. P. Alijanipour, Dr. M.J. Heffernan, Dr. N.K. Baldwin and Dr. A. King
Plenary Hall - New Techniques, Medical Economics Session from 3:50 to 5:00pm
Meeting attendees are invited to learn more about Medicrea at Booth #F16. To meet with Medicrea at Eurospine 2017 or express your interest in attending the official European UNiD™ HUB Launch event on Wednesday, October 11th, please contact Stephanie Sallamand at ssallamand@medicrea.com .
About Medicrea ( www.Medicrea.com )
Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 150,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.
For further information, please visit: Medicrea.com .
Connect with Medicrea:
FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE
Medicrea is listed on
EURONEXT Growth Paris
ISIN:
FR 0004178572
Ticker: ALMED
LEI:
969500BR1CPTYMTJBA37
View source version on businesswire.com: http://www.businesswire.com/news/home/20171010006835/en/
Contact:
Medicrea
Denys Sournac
Founder, Chairman and CEO
dsournac@Medicrea.com
or
Fabrice
Kilfiger, +33 (0)4 72 01 87 87
Chief Financial Officer
fkilfiger@Medicrea.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 14:00:00 CEST | Press release
New instrument automates tissue processing for researchers in cancer, immunology and other science fields To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom